Schedule I - Condensed Financial Information of Registrant - Parent Company Condensed Statements of Income (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues:
Total revenues	$ 185,340	$ 179,744	$ 309,893	$ 329,219	$ 401,332	$ 385,813	$ 442,408	$ 545,165	$ 1,004,196	$ 1,774,718	$ 1,435,413
Costs and expenses:
Selling, general and administrative									372,672	468,857	355,573
Research and development									73,887	76,850	75,316
Gain on sale of GeneDx									(18,559)	(31,508)	0
Total costs and expenses	240,610	267,564	320,632	401,643	464,416	347,987	436,837	506,728	1,230,449	1,755,968	1,377,699
Operating loss									(226,253)	18,750	57,714
Other income and (expense), net:
Interest income									1,981	28	152
Interest expense									(12,056)	(18,880)	(21,934)
Fair value changes of derivative instruments, net									649	846	50
Other income (expense), net									(155,842)	(14,769)	12,701
Other income and (expense), net									(165,268)	(32,775)	(9,031)
Loss before income taxes and investment losses									(391,521)	(14,025)	48,683
Income tax provision									63,499	(15,489)	(17,617)
Net loss before investments and loss from subsidiaries									(328,022)	(29,514)	31,066
Loss from investments in investees									(383)	(629)	(480)
Net income (loss)	$ (85,231)	$ (86,091)	$ (101,650)	$ (55,433)	$ (73,775)	$ 28,739	$ (16,186)	$ 31,078	(328,405)	(30,143)	30,586
Products
Revenues:
Total revenues									142,845	141,770	119,952
Costs and expenses:
Costs of revenue									88,429	91,022	70,509
Transfer Of Intellectual Property And Other [Member]
Revenues:
Total revenues									105,721	25,842	53,219
Parent Company
Revenues:
Total revenues									0	0	1,069
Costs and expenses:
Costs of revenue									2,347	1,279	260
Selling, general and administrative									46,882	66,483	41,736
Research and development									4,196	2,029	1,951
Gain on sale of GeneDx									(18,559)	0	0
Total costs and expenses									34,866	69,791	43,947
Operating loss									(34,866)	(69,791)	(42,878)
Other income and (expense), net:
Interest income									1,762	334	967
Interest expense									(13,688)	(21,297)	(23,585)
Fair value changes of derivative instruments, net									12	(58)	(46)
Other income (expense), net									(154,807)	(9,013)	10,354
Other income and (expense), net									(166,721)	(30,034)	(12,310)
Loss before income taxes and investment losses									(201,587)	(99,825)	(55,188)
Income tax provision									(10)	(2)	(175)
Net loss before investments and loss from subsidiaries									(201,597)	(99,827)	(55,363)
Loss from investments in investees									(383)	(629)	(480)
Net income (loss) from subsidiaries, net of taxes									(126,425)	70,313	86,429
Net income (loss)									(328,405)	(30,143)	30,586
Parent Company | Products
Revenues:
Total revenues									0	0	0
Parent Company | Transfer Of Intellectual Property And Other [Member]
Revenues:
Total revenues									$ 0	$ 0	$ 1,069